Healthcare
Lexicon Pharmaceuticals, Inc.(LXRX)
Live Price
Offline$2.01
-1.47% today
1Y Change
+123.33%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $690.00M
- Revenue Growth
- +60.2%
- EPS Growth
- +77.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lexicon Pharmaceuticals, Inc. (LXRX) is a Healthcare stock with a market cap of $690.00M and listed on NASDAQ. The stock last traded around $2.01 and up 123.3% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +60.2%, EPS growth of +77.8%, a dividend yield of 0.0%. What stands out right now is revenue +60.2%, EPS +77.8%, free cash flow +62.3% with operating margin -98.2% and ROIC -28.7%. Valuation already assumes a fairly strong business story at price/sales 13.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines LXRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+60.2% vs +7.6% peer median
Operating Margin
Below sector median
-98.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +60.2% and EPS at +77.8%, with operating margin around -98.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +1.2% | -11.6% | -22.0% |
2026 Mar 5, 2026 | +42.9% | +4.3% | +4.9% | -3.0% |
2025 Nov 6, 2025 | +42.9% | -12.6% | +0.7% | -2.1% |
Benchmark Edge
LXRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LXRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LXRX Max Drawdown
-34.09%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LXRX and SPY.
Company Overview
Lexicon Pharmaceuticals, Inc.
NASDAQ Global Select
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
- Leadership
- Michael S. Exton
- IPO Date
- Apr 7, 2000
- Employees
- 103
- Street Address
- 2445 Technology Forest Boulevard
- Mailing
- The Woodlands, TX, 77381
- Region
- The Woodlands, TX, US
- Reporting Currency
- USD
- Investor Line
- 281 863 3000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 13.9
- Price/Book
- 5.5
Growth
- Revenue
- +60.2%
- EPS
- +77.8%
- Free Cash Flow
- +62.3%
Profitability
- Gross Margin
- 98.9%
- Operating Margin
- -98.2%
- Net Margin
- -101.1%
- ROE
- -41.9%
- ROIC
- -28.7%
Balance Sheet
- Debt/Equity
- 0.58
- Current Ratio
- 4.88
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.